Setmelanotide
Imcivree / RM-493
- Peptide length
- 8 amino acids
Cyclic peptide
Open the sources to check how the studies were done and what they can support.
An MC4-receptor agonist used for specific causes of obesity. The 2026 FDA label includes acquired hypothalamic obesity alongside defined genetic conditions.
- Family
- Melanocortin receptor agonist
- Research target
- Melanocortin 4 receptor
- Molecular form
- Cyclic peptide
What to know about the research
Eligibility depends on the exact labeled condition and age group. This is not evidence for general obesity treatment.
Check the exact compound
Distinguish setmelanotide from other melanocortin agonists; shared receptor language does not imply the same clinical indication.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries